<DOC>
	<DOCNO>NCT00694993</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomized single dose escalation study double-blind , placebo-controlled , randomised parallel group 14-days daily repeat dose study investigate safety , tolerability pharmacokinetics intranasal H1/H3 dual antagonist compound healthy male subject .</brief_summary>
	<brief_title>Single Repeat Dose First Time Human Study Intranasal H1/H3 Dual Antagonist Healthy Male Subjects</brief_title>
	<detailed_description>A double-blind , placebo-controlled , randomized single dose escalation study double-blind , placebo-controlled , randomised parallel group 14-days daily repeat dose study investigate safety , tolerability pharmacokinetics intranasal H1/H3 dual antagonist compound healthy male subject .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Male subject age 18 50 year inclusive . Body mass index within range 1929.9kg/m2 ( inclusive ) , weight range 50 kg100 kg ( inclusive ) . Healthy ( defined individual free significant nasal , cardiac , pulmonary , gastrointestinal , hepatic , renal , haematological , malignancy , endocrine , neurological psychiatric disease determine history , physical examination screen investigation ) . Nonsmoking status verify urinary cotinine level 500 ng/mL cotinine screen visit . This include exsmokers give smoke &gt; 1 year . Normal nasal examination per Ear , Nose Throat ( ENT ) assessment No significant ECG abnormality QTc ( B ) &lt; 450 msec . The subject able willing give write informed consent take part study available complete study measurement . Male subject must agree abstain use condom sexual intercourse female partner childbearing potential , prevent either pregnancy female partner possible exposure pregnant lactate female investigational product male subject 's semen . In addition , female partner male subject must use reliable contraceptive method list protocol , must refrain sexual intercourse first dose study medication 84 day last dose . As result medical interview , physical examination screen investigation , Investigator appropriately qualify designee considers subject unfit study . The subject history drug allergy , , opinion Investigator appropriately qualify designee , contraindicate participation , include know suspected personal history family history adverse reaction hypersensitivity anti histamines The subject participate study new molecular entity previous 3 month study previous 2 month . The subject regularly , average , drink 21 unit alcohol week average intake 3 unit per day . The subject currently take regular ( course ) medication , prescribe ( include betaagonists ) ( include counter medication herbal remedy St Johns Wort ) . Paracetamol exception permit daily dos 4g follow first dose investigational product . The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV . The subject positive drug abuse alcohol test . Donation study would result &gt; 500mL blood donate 56 day period Subjects structural nasal abnormality frequent nose bleeds , Perennial Allergic Rhinitis ( PAR ) Seasonal Allergic Rhinitis ( SAR ) unless subject SAR asymptomatic outside pollen season Subjects unable comply study procedure Subject Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study Vulnerable subject ( eg . person keep detention )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>first time human</keyword>
	<keyword>Allergic rhinitis ,</keyword>
</DOC>